English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are severe cutaneous adverse reactions, are associated with fatal disorders.1 Although many causes of SJS/TEN have been proposed, their pathogenesis is not fully understood. Hypersensitivity to medications accounts for the majority of cases of SJS/ TEN.2 Several research groups have presented reports on drugs implicated in SJS/TEN (selective cyclooxygenase-2 inhibitors, lamotrigine, anti-epileptic drugs, sulfonamide antibiotics, and allopurinol, etc.).3,4 SJS associated with Mycoplasma pneumoniae infection is observed mainly in children,5,6 while another group reported the effects of the genetic background of patients.7 The relationship between aging and SJS/TEN is still not clear. Since SJS/TEN are very rare diseases,1 the implementation phase of epidemiologic research is fraught with difficulties. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is the largest and most well-known database worldwide, and it reflects the realities of clinical practice.8 FAERS, therefore, is one of the primary tools used in pharmacovigilance. We examined the incidence of SJS/TEN in the FAERS database from January 2004 to March 2013. To extract case reports of SJS/ TEN from the FAERS database, SJS/TEN were coded according to the terminology preferred by the Medical Dictionary for Regulatory Activities 16.0. We used the following three preferred terms to match SJS and TEN: SJS/PT10042033, oculomucocutaneous syndrome/PT10030081, and TEN/PT10044223. To detect SJS/TEN incidences, we calculated the reporting odds ratio (ROR), which is established for pharmacovigilance by using a disproportionality analysis.8 The ROR is an applicable technique that allows for adjustment through logistic regression analysis and offers the advantageous possibility of controlling for covariates.9 We refined the results with a dedicated correction to detect possible confounders present in the database. The reports were stratified by age as follows: 17 years, 18e39 years, 40e59 years, 60e79 years, and 80 years. The RORs were adjusted for gender, reporting year, and stratified age group. The following logistic model was used:

Stevens–Johnson syndrome and toxic epidermal necrolysis: The Food and Drug Administration adverse event reporting system, 2004–2013